| Metformin | diabetes type 2, in all type of patients | vs placebo | NS | NS | NS | NS | NS | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 1.45 [0.52 4.00] | p=1.00 | 0 | 490 | 2 | Teupe, Kooy (HOME), | | stroke (fatal and non fatal) | 0.99 [0.39 2.48] | p=1.00 | 0 | 490 | 2 | Teupe, Kooy (HOME), | | myocardial infarction (fatal and non fatal) | 1.14 [0.65 2.02] | p=1.00 | 0 | 490 | 2 | Teupe, Kooy (HOME), | | microvascular events | 1.04 [0.75 1.44] | p=1.00 | 0 | 390 | 1 | Kooy (HOME), | | macrovascular or microvascular events | 0.92 [0.72 1.18] | p=1.00 | 0 | 390 | 1 | Kooy (HOME), | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Teupe, 1991 | 1.700 | Placebo | Type 2 diabetic patients | | Kooy (HOME), 2009 | 2.000 | Placebo | Patients with type 2 diabetes |
|
| Metformin | diabetes type 2, in all type of patients | vs SU/Insulin | NS | NS | NS | NS | - | NS | NS | NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.73 [0.52 1.03] | p=1.00 | 0 | 1293 | 1 | UKPDS (vs SU or INS), | | stroke (fatal and non fatal) | 0.56 [0.30 1.05] | p=1.00 | 0 | 1293 | 1 | UKPDS (vs SU or INS), | | myocardial infarction (fatal and non fatal) | 0.78 [0.53 1.14] | p=1.00 | 0 | 1293 | 1 | UKPDS (vs SU or INS), | | microvascular events | 0.90 [0.56 1.45] | p=1.00 | 0 | 1293 | 1 | UKPDS (vs SU or INS), | | macrovascular or microvascular events | no data | | Peripheral vascular events | 1.39 [0.52 3.73] | p=1.00 | 0 | 1293 | 1 | UKPDS (vs SU or INS), | | Diabetes-related death | 0.76 [0.49 1.17] | p=1.00 | 0 | 1293 | 1 | UKPDS (vs SU or INS), | | Any diabetes-related outcomes | 0.78 [0.60 1.02] | p=1.00 | 0 | 1293 | 1 | UKPDS (vs SU or INS), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| UKPDS (vs SU or INS), 0 | 2.550 | SU/Insulin | Type 2 diabetic patients |
|
| Metformin | diabetes type 2, in all type of patients | vs Glipizide | - | - | NS | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | 1.00 [0.02 52.54] | p=1.00 | 0 | 48 | 1 | Campbell, | | microvascular events | no data | | macrovascular or microvascular events | no data | | Peripheral vascular events | no data | | Diabetes-related death | no data | | Any diabetes-related outcomes | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Campbell, 1994 | 1.000 | Glipizide | |
|
